This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lee, S. H. Articles by Yoo, N. J. Search for Related Content PubMed PubMed Citation Articles by Lee, S. H. Articles by Yoo, N. J.

Alterations of Fas (APO-1/CD95) Gene in Transitional Cell Carcinomas of Urinary Bladder¹

Departments of Pathology [S. H. L., M. S. S., W. S. P., S. Y. K., S. M. D., J. H. P., H. K. L., C. S. K., S. H. K., J. Y. L., N. J. Y.] and Biochemistry [H. S. K.], and Cancer Research Institute [S. H. L., W. S. P., J. Y. L., N. J. Y.], College of Medicine, The Catholic University of Korea, Seoul 137-701, Korea, and Department of Pathology and Cancer Research Center, Seoul National University College of Medicine, Seoul 110-799, Korea [J. J. J.]

Fas (Apo-1/CD95) is a cell-surface receptor involved in cell death signaling. The key role of the Fas system in negative growth regulation has been studied mostly within the immune system, and somatic mutations of Fas in cancer patients have been described solely in lymphoid-lineage malignancies. We analyzed somatic mutations and loss of heterozygosity of Fas gene in 43 transitional cell carcinomas of urinary bladder. Overall, 12 tumors (28%) were found to have Fas mutations, including 11 missense mutations and 1 frameshift mutation. Ten of the 12 mutations were located in the death domain known to be involved in the transduction of an apoptotic signal, and 8 of these 10 mutations showed an identical G to A transition at bp 993, indicating a potential hotspot in bladder cancers. Three of eight (38%) informative tumors carrying Fas mutations showed LOH at polymorphic sites in the promoter region. This is the first report on the Fas gene mutations in nonlymphoid malignancies, and our data suggest that alterations of the Fas gene might lead to the loss of its apoptotic function and contribute to the pathogenesis of some bladder cancers.

This article has been cited by other articles:

				M. Yang, T. Sun, L. Wang, D. Yu, X. Zhang, X. Miao, J. Liu, D. Zhao, H. Li, W. Tan, et al. Functional Variants in Cell Death Pathway Genes and Risk of Pancreatic Cancer Clin. Cancer Res., May 15, 2008; 14(10): 3230 - 3236. [Abstract] [Full Text] [PDF]

				E. Contassot, K. Kerl, S. Roques, R. Shane, O. Gaide, M. Dupuis, A. H. Rook, and L. E. French Resistance to FasL and tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in Sezary syndrome T-cells associated with impaired death receptor and FLICE-inhibitory protein expression Blood, May 1, 2008; 111(9): 4780 - 4787. [Abstract] [Full Text] [PDF]

				K. D. Crew, M. D. Gammon, M. B. Terry, F. F. Zhang, M. Agrawal, S. M. Eng, S. K. Sagiv, S. L. Teitelbaum, A. I. Neugut, and R. M. Santella Genetic polymorphisms in the apoptosis-associated genes FAS and FASL and breast cancer risk Carcinogenesis, December 1, 2007; 28(12): 2548 - 2551. [Abstract] [Full Text] [PDF]

				T. Sun, Y. Zhou, H. Li, X. Han, Y. Shi, L. Wang, X. Miao, W. Tan, D. Zhao, X. Zhang, et al. FASL -844C polymorphism is associated with increased activation-induced T cell death and risk of cervical cancer J. Exp. Med., October 3, 2005; 202(7): 967 - 974. [Abstract] [Full Text] [PDF]

				G. W. Wolkersdorfer, C. Marx, J. Brown, S. Schroder, M. Fussel, E. P. Rieber, E. Kuhlisch, G. Ehninger, and S. R. Bornstein Prevalence of HLA-DRB1 Genotype and Altered Fas/Fas Ligand Expression in Adrenocortical Carcinoma J. Clin. Endocrinol. Metab., March 1, 2005; 90(3): 1768 - 1774. [Abstract] [Full Text] [PDF]

				C. Ruiz-Ruiz, G. Robledo, E. Cano, J. M. Redondo, and A. Lopez-Rivas Characterization of p53-mediated Up-regulation of CD95 Gene Expression upon Genotoxic Treatment in Human Breast Tumor Cells J. Biol. Chem., August 22, 2003; 278(34): 31667 - 31675. [Abstract] [Full Text] [PDF]

				E. M. Maggio, A. van den Berg, D. de Jong, A. Diepstra, and S. Poppema Low Frequency of FAS Mutations in Reed-Sternberg Cells of Hodgkin's Lymphoma Am. J. Pathol., January 1, 2003; 162(1): 29 - 35. [Abstract] [Full Text] [PDF]

				L. Shen, A. C. T. Liang, L. Lu, W. Y. Au, Y.-L. Kwong, R. H. S. Liang, and G. Srivastava Frequent Deletion of Fas Gene Sequences Encoding Death and Transmembrane Domains in Nasal Natural Killer/T-Cell Lymphoma Am. J. Pathol., December 1, 2002; 161(6): 2123 - 2131. [Abstract] [Full Text] [PDF]

				H. Takayama, T. Takakuwa, Y. Tsujimoto, Y. Tani, N. Nonomura, A. Okuyama, S. Nagata, and K. Aozasa Frequent Fas Gene Mutations in Testicular Germ Cell Tumors Am. J. Pathol., August 1, 2002; 161(2): 635 - 641. [Abstract] [Full Text] [PDF]

				M. S. Shin, H. S. Kim, C. S. Kang, W. S. Park, S. Y. Kim, S. N. Lee, J. H. Lee, J. Y. Park, J. J. Jang, C. W. Kim, et al. Inactivating mutations of CASP10 gene in non-Hodgkin lymphomas Blood, May 13, 2002; 99(11): 4094 - 4099. [Abstract] [Full Text] [PDF]

				M. Müschen, D. Re, A. Bräuninger, J. Wolf, M.-L. Hansmann, V. Diehl, R. Küppers, and K. Rajewsky Somatic Mutations of the CD95 Gene in Hodgkin and Reed-Sternberg Cells Cancer Res., October 1, 2000; 60(20): 5640 - 5643. [Abstract] [Full Text]

				S. Brandau, H. Suttmann, J. Riemensberger, U. Seitzer, J. Arnold, C. Durek, D. Jocham, H.-D. Flad, and A. Böhle Perforin-mediated Lysis of Tumor Cells by Mycobacterium Bovis Bacillus Calmette-Guerin-activated Killer Cells Clin. Cancer Res., September 1, 2000; 6(9): 3729 - 3738. [Abstract] [Full Text]

				S. H. Lee, M. S. Shin, H. S. Kim, H. K. Lee, W. S. Park, S. Y. Kim, J. H. Lee, S. Y. Han, J. Y. Park, R. R. Oh, et al. Alterations of the DR5/TRAIL Receptor 2 Gene in Non-Small Cell Lung Cancers Cancer Res., November 1, 1999; 59(22): 5683 - 5686. [Abstract] [Full Text] [PDF]